引用次数
引用: 16,031
H-指数: 55
I10-指数 : 97
出版物: 261
Telomeres and human aging
G Saretzki , von, Zglinicki, T , Serra , R Lenzen-Grossimlighaus
Zeitschrift Fur Gerontologie Und Geriatrie
2
1999
Extracellular superoxide dismutase is a major antioxidant and slows down telomere shortening in human fibroblasts
M Lorenz , G Saretzki , von, Zglinicki, T , Serra
Free Radical Research: Meeting on Free Radicals and Oxidative Stress
1
2003
Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma
Caroline E Gleason , Mark A Dickson , Mary E Klein , Cristina R Antonescu
Clinical Cancer Research 30 ( 4) 703 -718
5
2024
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Rowan E Miller , Alexandra Leary , CL Scott , Violetta Serra
Annals of Oncology 31 ( 12) 1606 -1622
14
2020
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, PreventsPI3K Signaling and Inhibitsthe Growth of Cancer Cellswith Activating PI3K Mutations
Violeta Serra , Ben Markman , Maurizio Scaltriti , Pieter JA Eichhorn
908
2008
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Xing Yi Woo , Jessica Giordano , Anuj Srivastava , Zi-Ming Zhao
Nature Genetics 53 ( 5) 761 -761
2021
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
Albert Gris-Oliver , Yasir H Ibrahim , Martín A Rivas , Celina García-García
British Journal of Cancer 124 ( 9) 1581 -1591
8
2021
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
Dimitra Georgopoulou , Maurizio Callari , Oscar M Rueda , Abigail Shea
Nature Communications 12 ( 1) 1998 -1998
2021
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity.
Violeta Serra , Pieter Johan Adam Eichhorn , Jordi Rodon , Natali Vasilevski
Cancers 13 ( 7) 1538
27
2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Jan Rekowski , Bora Gurel , Johann S de Bono , Suzanne Carreira
Cancer Discovery
2021
Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers
Violeta Serra , Cristina Cruz , Marta Castroviejo , Sara Gutiérrez
Clinical Cancer Research 22
2016
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Jennifer L. Green , Eric S. Okerberg , Josilyn Sejd , Marta Palafox
Molecular Cancer Therapeutics 18 ( 4) 771 -779
8
2019
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty , Ayana Sawai , Maurizio Scaltriti , Vanessa Rodrik-Outmezguine
Cancer Cell 19 ( 1) 58 -71
1,015
2011
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
Maurizio Scaltriti , Pieter J. Eichhorn , Javier Cortés , Ludmila Prudkin
Proceedings of the National Academy of Sciences 108 ( 9) 3761 -3766
348
2011
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple- negative breast cancer
Ivana Zagorac , Sara Fernandez-Gaitero , Renske Penning , Harm Post
Nature Communications 9 ( 1) 3501 -3501
19
2018
Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity
Barbara Mair , Tomasz Konopka , Claudia Kerzendorfer , Katia Sleiman
PLOS Genetics 12 ( 9) e1006279
31
2016
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival
Balázs Györffy , Violeta Serra , Karsten Jürchott , Rula Abdul-Ghani
Oncogene 24 ( 51) 7542 -7551
57
2005
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Dick H.W. Dekkers , Jeroen A.A. Demmers , Dik C. van Gent , Reuven Agami
Journal of Clinical Investigation 126 ( 8) 2903 -2918
62
2016
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Violeta Serra , Pieter J.A. Eichhorn , Celina García-García , Yasir H. Ibrahim
Journal of Clinical Investigation 123 ( 6) 2551 -2563
85
2013
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
Isabel Puig , Stephan P Tenbaum , Irene Chicote , Oriol Arques
Journal of Clinical Investigation 128 ( 9) 3887 -3905
26
2018